Navigation Links
Isis Reports Positive Phase 1 Data Demonstrating ISIS-APOCIIIRx Produces Significant Reductions in apoC-III Protein Levels and Triglycerides
Date:12/6/2011

gle and multiple doses ranging from 50 mg per week up to 400 mg per week in 32 subjects.  

After only four weeks of dosing, subjects in the 200 mg and 400 mg multiple-dose cohorts displayed a median reduction of 71 percent and 78 percent in apoC-III levels, respectively, with two of the three treated subjects at the 400 mg dose reaching undetectable levels of apoC-III.  Additionally, in the 200 mg and 400 mg dose cohorts, subjects that received ISIS-APOCIIIRx had a median reduction in blood triglyceride levels of 43 percent and 44 percent, respectively, from baseline.  These statistically significant reductions were sustained for up to four weeks after the last dose.  ISIS-APOCIIIRx demonstrated a good safety profile and was well tolerated in all subjects with no clinically meaningful elevations of transaminase enzymes and no significant adverse events.  Isis will report the full data from this study at an upcoming scientific conference in 2012.

"In this Phase 1 study we observed substantial dose-dependent reductions of apoC-III protein and triglycerides, two independent risk factors for cardiovascular disease.   This is very encouraging data and underscores the therapeutic potential that a selective apoC-III inhibitor could offer patients with elevated levels of triglycerides and other atherogenic lipids, such as apoC-III.  In addition, since ISIS-APOCIIIRx specifically reduces apoC-III, it should substantially reduce triglycerides without the undesirable side effects that are associated with current therapies," said Walter Singleton, M.D., Vice President, Development and Chief Medical Officer at Isis.  "ISIS-APOCIIIRx is a key component of our cardiovascular franchise strategy to treat all aspects of cardiovascular disease by targeting pro-inflammatory and other atherogenic particles.  We plan to initiate a proof-of-concept Phase 2 study evaluating the efficacy of ISIS-APOCIIIRx in treatment-naive pat
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... N.Y. , May 21, 2013  Vasomedical, Inc. (OTC ... in the design, manufacture and sale of medical devices and ... that Dr. Jun Ma , President and ... Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hyatt Hotel. The Company,s presentation is scheduled ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , ... NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today ... published online the positive Phase 2a study results ...  Dupilumab is an investigational monoclonal antibody targeting the alpha ... modulates signaling of both IL-4 and IL-13, drivers of ...
(Date:5/21/2013)... , May 21, 2013  BioRestorative Therapies, Inc. ("BRT" ... company focused on developing stem cell based therapies for ... , its President and CEO, will be presenting ... conference will be held on Thursday, May 30, 2013 ... 42nd Street in New York City.  Mr. Weinreb,s presentation ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... Inc., a privately-held developer and marketer of the ... system for measuring platelet reactivity to multiple antiplatelet ... published in The Annals of Thoracic Surgery ... as a new recommendation for preoperative patient assessment(1). ...
... Pa., March 9, 2011 ViroPharma Incorporated (Nasdaq: ... has authorized the use of up to $150 million to ... Convertible Notes due 2017. Purchases may be ... negotiated purchase transactions or other techniques from time to time, ...
Cached Medicine Technology:2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery 22011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery 3ViroPharma Announces Securities Repurchase Program 2ViroPharma Announces Securities Repurchase Program 3
(Date:5/21/2013)... genetic features of pulmonary fibrosis by physicians and scientists ... lead to improved treatment of this deadly lung disease, ... . , The study found that a particular genetic ... fibrosis, a chronic progressive disease with a median survival ... researchers may want to consider including genetic testing in ...
(Date:5/21/2013)... the adenoids and tonsils, is performed 500,000 times a ... for children with obstructive sleep apnea. However, the ... functioning, behavior, sleep apnea symptoms, and quality of life ... study led by Susan Redline, MD, MPH, director ... Associate Clinic Director of the Division of Sleep Medicine ...
(Date:5/21/2013)... Today, Zane Benefits, Inc. published a new ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution and http://HRA Link: ... Zane Benefits’ website, the Affordable Care Act (known as ... 2010 and impacts many areas of health care and ...
(Date:5/21/2013)... 2013 A new study appearing in ... that stem cells harvested from fat (adipose) are more ... to modulate the body’s immune system. , The ... therapies, as adipose tissue-derived stem cells (AT-SCs) are far ... bone marrow and can be collected from waste material ...
(Date:5/21/2013)... 21, 2013 Octo Consulting Group, ... management consulting solutions to the Federal marketplace, has ... In the newly created role, Denny will ... of the firm’s business development function to include ... functions, and leading strategies to achieve the firm’s ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
... Department of Antiquities of Syria and the University of Chicago ... fought in upper Mesopotamia// in 3500 B.C., leading to the ... that the entire area where the excavation was conducted was ... by the archeologists. Hamoukar is in Syria at the Iraqi ...
... related to Food science and consumer acceptance in Norway ... then do experts to cheese.// ,The food compared ... with expert dairy assessors. The rating was based on ... ,There was difference of opinion in both factions. As ...
... will be spending $60 million to buy 1.8 courses ... //Australian Health Minister Tony Abbott confirmed the order yesterday. ... to pharmaceuticals giant GlaxoSmithKline, but Biota had alleged that ... this allegation. This fresh order makes it the third ...
... has been conducted on a six-year-old Pakistani boy at the ... his birthday on 19 December 2005. //,Anupam Sibal, Medical Director ... in ICU but is responding well to medication. Doctors are ... be normal soon.' , ,He refused to give further ...
... Yoga, Acupuncture, Ayurveda, Chinese movement therapies such as ... just some of the commonly used alternative treatments ... Europe. //Perhaps, this is because it’s strongly perceived ... treatment for cancer with the combination of some ...
... of James Cook University's (JCU) has urged the Health ... the University which will help to produce more doctors ... graduation day.// James Cook University is Australia's premier tropical ... The University is named after the British explorer, Captain ...
Cached Medicine News:Health News:Excavations Reveal Clues Of Early Warfare 2
... system was expressly designed to obtain the ... special source and an equally special power ... particular high energy impulses with constant peak ... 'top-flat shaped') allow storage of enough energy ...
... Derm is a KTP laser, very compact ... nm (frequency doubled Nd:YAG) for dermatologic treatments. ... comfortable color LCD Touch-screen. Maximum power ... 0.3, 0.5, 0.7 and 1.0 mm. SmartLite ...
... Erbium (Er:YAG) laser is the ideal instrument ... Smart 2940 Plus, the majority of surface ... a wide range of scar tissue, with ... most cases with the elimination of anaesthetics, ...
... is the result of DEKA s ... of three different methods capable of ... skin. This treatment is designed to ... through the combined action of a ...
Medicine Products: